Cantor Fitzgerald’s Alto Neuroscience ANRO Stock Holding History

Cantor Fitzgerald’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40,000	Closed	-$88K	–	560
2025 Q2	$88K	Hold	40,000	–	–	﹤0.01%	359
2025 Q1	$86.4K	Sell	40,000 -335,000	-89%	-$1.2M	﹤0.01%	240
2024 Q4	$1.57M	Buy	+375,000	New	+$2.34M	0.03%	73

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cantor Fitzgerald's ANRO Position: Q3 2025 in Review

Cantor Fitzgerald sold out of Alto Neuroscience (ANRO) in Q3 2025, closing a stake of 40,000 shares — an estimated $88K sold.

Cantor Fitzgerald first reported a position in ANRO in Q4 2024 and held it in 3 quarters. The position peaked at $1.57M in Q4 2024. 77 funds tracked by Wall St. Rank hold ANRO as of Q3 2025.

Cantor Fitzgerald reported no remaining Alto Neuroscience position as of Q3 2025 after selling out during the quarter.
Cantor Fitzgerald sold 40,000 Alto Neuroscience shares in Q3 2025, an estimated $88K.
Cantor Fitzgerald first reported a position in Alto Neuroscience in Q4 2024 and held it in 3 quarters.
Cantor Fitzgerald's Alto Neuroscience position peaked at $1.57M in Q4 2024.
77 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.